Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

Number of participants with Adverse events will be covered in Adverse Events section.

The statistical analysis tests for the efficacy variables will be performed hierarchically.
The comparisons ciprofloxacin DPI vs. pooled placebo (according to statistical analysis plan
defined for FDA registration) will be performed in parallel for the regimen 28 days on/off
and 14 days on/off.

Inclusion Criteria:

- Patients with a proven and documented diagnosis of non Cystic Fibrosis (CF) idiopathic
or post infectious bronchiectasis

- Stable pulmonary status and stable regimen of standard treatment at least for the past
4 weeks

Exclusion Criteria:

- Forced expiratory volume in 1 second (FEV1) <30% or >90% predicted

- Active allergic bronchopulmonary aspergillosis

- Active and actively treated non tuberculosis mycobacterial (NTM) infection or
tuberculosis

- Primary diagnosis of Chronic obstructive pulmonary disease (COPD)